Drug, Diagnostic Firms Should Partner, Not Merge, To Personalize Medicine
Executive Summary
The drug and diagnostic industries should partner, not merge, to develop companion products, according to a diagnostics industry representative on a recent Personalized Medicine Coalition conference panel
You may also be interested in...
Companion Diagnostics Spark Pharma Deals - But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
Companion Diagnostics Spark Pharma Deals - But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
Companion Dx Pioneers Test Variety Of Business Models
Regulatory environment opens up, but alliances with Pharma have yet to take off.